The risk of hepatocellular carcinoma of the liver in non-alcoholic fatty liver disease: features of prevention and treatment

Relevance. Non-alcoholic fatty liver disease (NAFLD) is a multidisciplinary problem and occupies a significant place among chronic non-communicable diseases (CNCDs). The main causes of death from this nosology are cardiovascular pathology and neoplasms. This article discusses the main problems of underestimation of diagnosis in patients with high cardiovascular risk of NAFLD. In particular, attention is paid to the risks of developing hepatocellular carcinoma without previous cirrhosis. The aim of the study was to describe a typical portrait of a patient with a very high cardiovascular risk (CVR) with NAFLD and the features of the prevention of hepatocellular carcinoma (HC) in this category of patients. Research materials. The case history of a patient with stage 3 arterial hypertension, functional class II (FC) angina pectoris, postinfarction cardiosclerosis in combination with NAFLD in the stage of liver steatosis, stage 1 obesity, and impaired carbohydrate tolerance is presented. Results. Against the background of corrected antihypertensive therapy, blood pressure and heart rate returned to normal. The level of transaminases approached the reference values, there was a tendency to reduce total cholesterol, low density lipoproteins, triglycerides. According to volumetric sphygmography, vascular age began to approach the passport age, the augmentation index became within negative values, the ankle-brachial index remained unchanged, and an increase in endothelial function was observed. Conclusion. This clinical case provides an example of successful treatment of NAFLD and dyslipidaemia in a patient with very high CV risk. With this in mind, it is necessary to timely use drugs that directly affect the stages of the formation and progression of NAFLD, which should be actively prescribed for the prevention of GC.

non-alcoholic fatty liver disease, arterial hypertension, coronary heart disease, steatosis, hepatocellular carcinoma

1. Huang D. Q., El-Serag H.B., Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021; 18: 223-238.

2. Ivashkin V. T., Drapkina O. M., Maev I. V., et al. The prevalence of non-alcoholic fatty liver disease in outpatients in the Russian Federation: results of the DIREG 2 studyю. RJGK. 2015; 6:31-41. (in Russ.) @@Ивашкин В. Т., Драпкина О. М., Маев И. В. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. РЖГК. 2015;6:31-41.

3. Younossi Z.M., Koenig A. B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology.2016;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. PMID: 26707365.

4. Lonardo A., Nascimbeni F., Mantovani A., et al. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68(2):335-52. doi: 10.1016/j.jhep.2017.09.021

5. Lee D. H., Lee J. M. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol. 2017;95:349-361.

6. Kapil S., Duseja A., Sharma B. K., et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31(1):213-221. doi:10.1111/jgh.13058

7. Siegel R. L., Miller K. D., Jemal A. Cancer statistics. 2018. CA Cancer J Clin. 2018;68(1):7-30. doi:10.3322/caac.21442

8. Younossi Z. M., Henry L. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. Pharmacoeconomics. 2015;33(12):1245-1253. doi:10.1007/s40273-015-0316-5

9. Rahman R., Hammoud G. M., Almashhrawi A. A., et al. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013;5(9):186-194. doi:10.4251/wjgo.v5.i9.186

10. Tomimaru Y., Koga H., Yano H., et al. Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int. 2013;33(7):1100-1112. doi:10.1111/liv.12188

11. Schütte K., Schulz C., Poranzke J., et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol. 2014;14:117.

12. Hofmann A. F. Biliary secretion and excretion in health and disease: current concepts. Ann Hepatol. 2007;6(1):15-27.

13. Omata M., Cheng A. L., Kokudo N., et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-370. doi:10.1007/s12072-017-9799-9

14. Drapkina O. M. Bueverova E. L. Ivashkin V. T. Atherogenic dyslipidemia and the liver. Atherosclerosis and Dyslipidemia. 2010;1:25-31. (in Russ.) @@Драпкина О. М. Буеверова Е. Л. Ивашкин В. Т. Атерогенная дислипидемия и печень. Атеросклероз и Дислипидеми. 2010; 1: 25-31

15. Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnosis, treatment. Recommendations for therapists, third version. Experimental and clinical gastroenterology. 2021;185(1): 4-52. (in Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52 @@Лазебник Л. Б., Голованова Е. В., Туркина С. В. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52

16. Vos M.B., Abrams S. H., Barlow S. E., et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319-334. doi: 10.1097/MPG.0000000000001482

17. Mayevskaya M. V., Nadinskaia M. Yu., Lunkov V. D., et al. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non Alcoholic Fatty Liver Disease: Results of the USPEH Study.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019; 29(6):22-29. (In Russ.) doi:10.22416/1382-4376-2019-29-6-22-29 @@Маевская М. В., Надинская М. Ю., Луньков В. Д., и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):22-9

18. Nikitin I. G., Volnukhin A. V. Cholelithiasis: epidemiological data, key aspects of the pathogenesis and comorbidity, relevant therapeutic targets.Russian Medical Inquiry. 2020;4(5):290-296. (in Russ.) doi: 10.32364/2587-6821-2020-4-5-290-296 @@Никитин И. Г., Волнухин А. В. Желчнокаменная болезнь: эпидемиологические данные, ключевые аспекты патогенеза и коморбидности, актуальные терапевтические мишени. РМЖ. Медицинское обозрение. 2020;4(5):290-296. doi:10.32364/2587-6821-2020-4-5-290-296.